Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs

By | 8 June 2026

Exploring how Topo1 and Topo1 ADCs elicit immunogenic cell stress in vivo through the induction of cellular senescence
Delineating the host immune cell requirements for Topo1-induced immunogenicity
Identifying biomarkers of immunogenic cell stress mediated by Topo1 ADCs